169 related articles for article (PubMed ID: 33086575)
1. Non-Muscle-Invasive Bladder Carcinoma with Respect to Basal Versus Luminal Keratin Expression.
Jung M; Jang I; Kim K; Moon KC
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086575
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
3. Dynamic expression changes between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.
Zhao YG; Shi BY; Qian YY; Bai HW; Xiao L; He XY
Tumori; 2014; 100(6):e273-81. PubMed ID: 25688510
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.
Piao XM; You C; Byun YJ; Kang HW; Noh J; Lee J; Lee HY; Kim K; Kim WT; Yun SJ; Lee SC; Kang K; Kim YJ
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884561
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer.
Chen MK; Chen ZJ; Xiao KH; Qin ZK; Ye YL; Wen WJ; Bian J; Xue KY; Zhou QZ; Guo WB; Zhou JH; Xia M; Li X; Liu CD
Jpn J Clin Oncol; 2020 Apr; 50(4):456-464. PubMed ID: 31894237
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.
Kim WJ; Kim EJ; Kim SK; Kim YJ; Ha YS; Jeong P; Kim MJ; Yun SJ; Lee KM; Moon SK; Lee SC; Cha EJ; Bae SC
Mol Cancer; 2010 Jan; 9():3. PubMed ID: 20059769
[TBL] [Abstract][Full Text] [Related]
7. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
8. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
Lelo A; Prip F; Harris BT; Solomon D; Berry DL; Chaldekas K; Kumar A; Simko J; Jensen JB; Bhattacharyya P; Mannion C; Kim JS; Philips G; Dyrskjøt L; Waldman T
Clin Cancer Res; 2018 Sep; 24(17):4145-4153. PubMed ID: 29954776
[No Abstract] [Full Text] [Related]
9. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
Silva TA; Azevedo H
J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
[TBL] [Abstract][Full Text] [Related]
10. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
[TBL] [Abstract][Full Text] [Related]
12. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer.
Dhawan D; Hahn NM; Ramos-Vara JA; Knapp DW
PLoS Genet; 2018 Aug; 14(8):e1007571. PubMed ID: 30089113
[TBL] [Abstract][Full Text] [Related]
13. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
14. Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
Blinova E; Roshchin D; Kogan E; Samishina E; Demura T; Deryabina O; Suslova I; Blinov D; Zhdanov P; Osmanov U; Nelipa M; Kaprin A
Cells; 2019 May; 8(6):. PubMed ID: 31159302
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
16. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.
Biton A; Bernard-Pierrot I; Lou Y; Krucker C; Chapeaublanc E; Rubio-Pérez C; López-Bigas N; Kamoun A; Neuzillet Y; Gestraud P; Grieco L; Rebouissou S; de Reyniès A; Benhamou S; Lebret T; Southgate J; Barillot E; Allory Y; Zinovyev A; Radvanyi F
Cell Rep; 2014 Nov; 9(4):1235-45. PubMed ID: 25456126
[TBL] [Abstract][Full Text] [Related]
17. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
18. Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.
Lima L; Neves M; Oliveira MI; Dieguez L; Freitas R; Azevedo R; Gaiteiro C; Soares J; Ferreira D; Peixoto A; Fernandes E; Montezuma D; Tavares A; Ribeiro R; Castro A; Oliveira M; Fraga A; Reis CA; Santos LL; Ferreira JA
Urol Oncol; 2017 Dec; 35(12):675.e1-675.e8. PubMed ID: 28911924
[TBL] [Abstract][Full Text] [Related]
19. Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.
Yang D; Ma Y; Zhao P; Ma J; He C
Biomed Pharmacother; 2019 Dec; 120():109433. PubMed ID: 31568988
[TBL] [Abstract][Full Text] [Related]
20. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]